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Summary We analysed 29 consecutive cases of primary gastric lymphoma (20 men and 9 women) treated in
our unit between January 1977 and May 1983. Median age was 55 years. Abdominal pain and weight loss
were the main presenting symptoms while there was no palpable disease in the majority of cases. Upper
gastrointestinal radiology was abnormal, but not diagnostic, in all cases. Endoscopy with multiple biopsies
was performed in 22 cases; carcinoma was diagnosed in 11, lymphoma in 8 while no diagnosis was made in 3
cases.
Twenty six patients underwent laparotomy. Gastrectomy was performed in twenty while the tumour was
unresectable in six. Histology was reported as diffuse in 28 cases (16 histiocytic, 8 lymphocytic and 4 mixed)
and nodular (lymphocytic) in one.
All our patients received multichemotherapy. Complete remission after 6 courses was documented in 18
patients (62%). Neither perforation nor gastrointestinal bleeding was a problem in our series. Eighty four per
cent complete responders are predicted to be alive at 4 years. Advanced stage (112B and IV) and tumour size
> 10 cm adversely influenced survival.
We suggest that in limited primary gastric lymphoma an attempt at 'curative' surgery combined with
multichemotherapy currently gives very promising results.
Primary gastric lymphoma (PGL) represents a
relatively uncommon gastric neoplasm accounting
for 5% of all gastric cancers (Conors & Wise,
1974; Contreary et al., 1980). However stomach is
the most common site of extranodal non Hodgkin's
lymphomas (Freeman et al., 1972).
The best treatment for PGL remains uncertain.
Although many of the reported series (Fleming
et al., 1982; Siu et al., 1982; Shimm et al., 1983)
demonstrate that surgical resection with post-
operative irradiation is the most effective treatment,
the role of chemotherapy as an initial treatment or
postoperatively remains to be clarified.
In this article we report our experience with PGL
with reference to histology, prognostic factors and
the results of combination chemotherapy with or
without gastric resection.
Materials and methods
Patients
By definition patients with PGL have disease
confined to stomach or stomach and its draining
nodes without evidence of dissemination and with
normal peripheral blood at the time of diagnosis
(Carr & Hancock, 1984). Applying these criteria we
were able to identify a total of 29 patients
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diagnosed and treated at the Haematology-
Oncology section of the Second Department of
Internal Medicine, Propaedeutic, Evangelismos
Hospital, Athens University, between January 1977
and May 1983.
One patient had a palpable node in the left
supraclavicular fossa at presentation but since
extensive staging procedures failed to demonstrate
disease elsewhere, stomach apart, this patient was
not excluded from the study.
The slides of the initial histology were reviewed
in all cases, the diagnosis of non-Hodgkin's
lymphoma was verified and the cases were finally
classified according to the modified Rappaport
Classification (1966).
Median follow up of the 29 patients was 29
months with a minimum of 18 months (range 18-79
months).
Staging
All patients were extensively staged on the basis of
clinical examination, surgical or endoscopial
findings, X-rays of the chest and upper gastro-
intestinal (GI) tract, full blood count, liver
function tests, bone marrow biopsy, liver biopsy,
lymphogram, CT-scan of the abdomen and bone
scan.
They were classified according to the Ann-Arbor
System (Carbone et al., 1971) with the only
modification that stage II disease was further
subdivided to stage II1 for those with perigastric or
mesenteric nodal involvement and stage 112 for
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those with involvement of the regional but not
confluent (paraortic or parailiac) lymph nodes
(Musshof, 1977).
Chemotherapy
The chemotherapeutic regimens used were either a
combination of cyclophosphamide, vinscristine and
prednisone (COP) or a combination of all the
above drugs plus adriamycin (CHOP). Details of
the two regimens are given in Table I. Fifteen
patients (51,5%) received COP and 14 patients
(48,5%) the CHOP regimen.
Assessment and definition ofresponse
All patients without evidence of disease progression
during chemotherapy were fully restaged after the
completion of 6 courses of treatment. Restaging
included clinical examination, full blood count, liver
function tests, chest-X-ray, X-rays of the upper GI
tract, endoscopy and CT scan of the abdomen.
Liver biopsy was repeated at the end of the six
courses only if the liver was initially involved.
Patients with complete disappearance of disease
and no abnormal findings at endoscopial biopsies
and liver biopsy were designated as being in
complete remission (CR).
Patients with no clinically evident disease, but
with laboratory evidence of residual disease and/or
abnormal liver biopsy were designated as partial
responders (PR). Patients with progressive disease
were designated as non-responders (NR).
Treatment policy
Twenty six patients (89%) underwent exploratory
laparotomy, while 3 (11%) patients proceeded to
chemotherapy after a diagnosis of lymphoma on
the basis ofendoscopical biopsy had been made.
All patients were given combination chemo-
therapy (CT). A total of 6 courses were given in all
responding patients and then full restaging was
performed (supra vide). Patients in documented CR
discontinued CT and they were closely followed up.
Patients in PR were given another 3 courses of the
same regimen. At this time, if CR was documented,
chemotherapy was discontinued while patients still
in the PR were given an alternative regimen at
the discretion of the physician. No patient in the
present series has received irradiation either pre-
operatively or postoperatively.
Statistics
Duration of survival was calculated from the
beginning of therapy until death. Survival curves
wereconstructedaccordingto themethodofKaplan-
Meier (1958). The significance of differences
between the various actuarial survival curves was
assessed by the long rank test.
Results
The patients comprised 20 men and 9 women and
the median age of the whole population was 55
years (range, 21-74).
The main clinical manifestations at presentation
and the radiological and endoscopical findings are
presented in Tables II and III.
Abdominal pain and weight loss were the com-
monest presenting symptoms. Clinical examination
revealed an abdominal mass in two instances (one
with splenomegaly) while lymphadenopathy was
present in one patient. No disease was palpable in
25 (86%) cases (Table II).
X-ray examination of the upper GI tract was
performed in all 29 patients. It was abnormal in all.
Radiological findings were interpreted as demon-
strating a gastric carcinoma in 28 (96.5%) patients
and benign ulcer in one (3.5%).
Endoscopy was performed in 22 cases. Tumour
mass and/or various mucosal abnormalities were
seen in all, and biopsies were taken from all lesions.
Macroscopical findings together with histology were
interpreted as showing gastric lymphoma in 8 (36%)
cases and gastric carcinoma in 11 (50%) cases,
while in the remaining three (14%) cases histology
was not diagnostic.
Surgery
A total of 26 patients underwent exploratory
laparotomy. A gastric resection with curative intent
was possible in 20 (77%) cases. It consisted of total
gastrectomy in 5 (25%) and subtotal gastrectomy in
15 (75%), depending entirely on the surgeon's
discretion. Tumour was considered unresectable in
Table I Chemotherapy regimes
COP CHOP
Cyclophosphamide 600mgm-2 days 1 and 8 Cyclophosphamide 500mg days 1 and 8
Vincristine 2mg days 1 and 8 Vincristine 2mg days 1 and 8
Prednisone 30mgm-2 days 1-8 Adriamycin 30mgm-2 days 1 and 8
Prednisone 40mgm-2 days 1-8PRIMARY GASTRIC LYMPHOMA 393
Table II Symptoms and clinical findings
Symptom No. pts (%) Clinicalfindings No. pts (%)
Pain 26 (89) Abdominal mass 1 (3.5)
Weight loss 22 (76) Abdominal mass+
G.I. bleeding 5 (17) Splenomegaly 1 3.5)
Vomiting 4 (14) Lymphadenopathy 1 (3.5)
Fever 4 (14) Non palpable disease 26 (88.5)
Dysphagia 2 (7)
Table Ill Radiological and endoscopical findings
Radiological Endoscopical
findings No/na (%) findings No/na (%)
Gastric carcinoma 28/29 (96.5) Lymphoma 8/22 (36)
Benign ulcer 1/29 (3.5) Gastric carcinoma 11/22 (50)
Gastric lymphoma 0/29 0 Non-diagnostic 3/22 (14)
Abnormal 29/29 (100) Abnormal 22/22 (100)
aNo/na Number present/Number performed.
6 (23%) cases either because of bulky disease (5
cases) or because of tumour spread beyond the
draining perigastric lymph nodes (one case).
Biopsies from suspicious mesenteric and/or
paraortic nodes together with blind biopsies from
the liver were taken in all cases.
Histology and stage
Tables IV and V summarize the results on the
histological type and stage of the disease. Twenty-
eight patients (96.5%) exhibited a diffuse architec-
tural pattern while only one showed a nodular
Table IV Histological classification
Histology No. pts (%)
Diffuse histiocytic 16 (55)
Diffuse mixed 4 (14)
Lymphocytic:
Diffuse poorly differentiated 8 (27.5)
Nodular poorly differentiated 1 (3.5)
Table V Staging of primary gastric lymphoma
Limited disease Disseminated disease
Stage No. pts (%) Stage No. pts (%)
I 3 (10) lI2B 7 (24)
111A 6 (21)
IIIB 9 (31) IV 4 (14)
Total 18 (62) Total 11 (38)
pattern. Sixteen cases (55%) had an histiocytic
cellular constituent, nine (31%) a lymphocytic
and four (14%) a mixed lymphocytic-histiocytic
component (Table IV).
Eighteen (62%) patients had limited disease
(Stages I, 111A, II1B) and 11 (48%) disseminated
disease (stages 112B and IV) (Table V).
All patients with stage IV were classified as such
by virtue of liver involvement.
Size situation and local invasion ofthe tumour
Size of the tumour varied from 2cm to 15cm in its
greater diameter. We have separated the patients
into two groups taking 10cm as an arbitrary
dividing line. The distribution is shown in Table VI.
In the same table patients are presented in four
categories according to the anatomical regions in
which the bulk of the tumour was situated. These
regions were determined according to the UICC
rules for the classification of gastric carcinoma
(TNM Classification, 1978).
Depth of invasion of the gastric wall was studied
in 20 patients who underwent gastrectomy. Results
are shown in Table VII expressed according to
UICC criteria for pTNM. (UICC 1978).
Response to treatment
Altogether 18 patients (62%) were found to have a
CR during full restaging after the completion of 6
courses of chemotherapy (Table VIII). Among
these, 15 had been treated postoperatively after
having had a curative gastric resection. Only 3
patients among the complete responders had been394 T. ECONOMOPOULOS et al.
Table VI Tumour size and situation
Tumour size No. pts (%) Tumour situation No. pts (%)
Upper third 2 (7)
< 10cm 13 (45) Middle third 17 (59)
Lower third 5 (17)
> 10cm 16 (55) Multiple lesions 5 (17)
Table VII Depth of invasion
Depth ofinvasion (pT) No. pts (%)
Mucosal and submucosal (pT1) 3 (15)
Muscuralis propia (pT2) 10 (50)
Serosal but without
invasion of contiguous
structures (pT3) 7 (35)
Table VIII Treatment response
Group ofpatients No CR(%) PR(%) NR(%)
Tumour resected 20 15(75) 4(20) 1(5)
Tumour nonresected 64
n9 3(33) 4(44.5) 2(22)
not operated on 32
Total number 29 18(62) 8(31) 3(10)
treated with CT without having had a previous
gastric resection.
Among the 20 patients who had gastric resection
15 (75%) were found to be in CR, 4 (20%) were
found to be in PR and one patient (5%) was a non
responder (Table VIII). Contrariwise, among the 9
patients with nonresected tumour 3 (33%) were
found to be in CR, 4 (44,5%) were found to be in
PR and 2 (22%) patients were non-responders.
Among the complete responders two patients
have relapsed so far. One belongs to the group of
patients with resected tumour and he relapsed
locally 6 months after CR had been documented.
The other belongs to the group of patients with
nonresected tumour. He relapsed in the small
intestine 20 months after documentation of CR. He
was operated upon and the entire macroscopic
disease was successfully resected. No evidence of
lymphoma was found in the stomach or elsewhere.
The patient has been currently receiving chemo-
therapy with Pro-MACE regimen (Fisher et al.,
1982). The remaining 16 patients are still in
complete remission.
Survival
The survival of all 29 patients is shown in Figure 1.
Median survival has not been reached. Acturial
analysis predicts that it will be in excess of 5 years
with 58% of patients alive at that time. Among the
complete responders 84% are predicted to be alive
at 4 years, whereas only 18% of the partial
responders and none of the non-responders are
predicted to survive, at 28 months.
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Figure 1 Actuarial survival of29 patients with primary
gastric lymphoma according to the response to
treatment. (0) all patients (18 alive; 11 dead); (@)
complete responders (17 alive, 1 dead); (A) partial
responders (1 alive, 6 dead); (El) non responders (4
dead).
Survival and modality oftreatment
The group of patients, treated with gastrectomy
plus chemotherapy had a significantly better
survival (P<0.05) than the group treated by
chemotherapy alone (Figure 2). The type of
chemotherapy (CHOP vs COP) had no significant
influence on survival.
Survival and extent ofthe disease
Size of tumour was found to be an important
prognostic discriminant. Those with tumours
<10cm had a better survival than those with
tumours >10cm (P<0.05 - Figure 3).PRIMARY GASTRIC LYMPHOMA 395
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Figure 2 Actuarial survival of29 patients with primary
gastric lymphoma according to the type of treatment.
(---) gastrectomized+CT, (15 alive, 5 dead): (-)
unresectable (3 alive, 6 dead).
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Figure 4 Influence of stage of the disease on survival.
(-) Stages IA,11IA,II1 B (14 alive, 4 dead); (---)
Stages II2B, IV (4 alive, 7 dead).
the past few years (Lim et al., 1977; Lewin et al.,
__ -1978; Hermann et al., 1980; Weingrand et al., 1982;
Brooks & Enterline, 1983) many relevant questions
L - _ _ _ on the subject remain unanswered. In particular, as
far as the best management of the disease is
concerned, the literature is inconclusive.
The main reasons for the existing controversy
are: (a) the small number of patients included in
each report (b) all studies are retrospective (c) the
variability of histological classifications used in the
various studies (d) the inconsistency in the use of a
I I I I I I staging system and (e) th lack of a consistent
0 10 20 30 40 50 60 70 80 therapeutic policy in almost all the published
Time (months) studies.
By contrast our study comprises 29 patients
r size <nOcm (II alive, 2 dead)s (a) tumour treated in a single institution. While we used
Ocm (7 alive1 9 dead). Rappaport's scheme for the classification of
lymphoma, all patients were staged using the Ann-
Arbor system. Moreover, we treated all our patients
of invasion was less discriminatory. uniformly with multi-chemotherapy, combined with
h the group of patients with invasion of the "curative" surgery where feasible.
id less well than those with invasion limited For the above reasons we feel that our results are
submucosa or muscularis propia, the ofparticular interest.
,e was not statistically significant. Our clinical and radiological findings as well as
nfluence of stage is shown in Figure 4. age and sex distribution do not differ essentially
with limited disease (stages IA, II1A, II1B) from those published in other series (Lim et al.,
better survival than those with advanced 1977; Lewin et al., 1978; Hermann et al., 1980).
stages 112B and IV - P<0.05). It is of interest to note however, that clinical
Ln survival for patients with limited disease examination was not contributory in 86% of our
attained at 6 years while it was 26 months cases while on the other hand dysphagia was found
with advanced disease. to be a rare presenting complaint.
Endoscopy and biopsy are not found especially
useful in our hands in making an accurate diagnosis
in of gastric lymphoma; it was not diagnostic in 14%
of cases while it was misinterpreted as gastric
the fact that a number of studies on carcinoma in another 50% of cases. The experience
gastric lymphoma have been published in of other investigators is similar (Flemming et al.,
1
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1982). In addition even a diagnostic endoscopy
usually fails to histologically subclassify this
lymphoma, and is never satisfactory for staging
purposes.
As far as the incidence of the various histological
categories is concerned our findings are essentially
similar to other series (Lim et al., 1977; Lewin et
al., 1978; Hermann et al., 1980). Using Rappaport's
Classification, we found that only one patient
(3.5%) demonstrated a nodular architectural
pattern. The cellular constituent was histiocytic in
55%, lymphocytic in 31% and mixed in 14% of
cases.
Several investigators have claimed that the Ann-
Arbor staging system is inappropriate for staging
gastrointestinal lymphomas (Blackledge et al., 1979;
Crowther & Rankin, 1982) and other staging
systems have been therefore designated (Lim et al.,
1977; Crowther & Rankin, 1982). Although we do
not disagree with the statement that the application
of the Ann-Arbor system is problematic in some
cases of lymphomas, its modified from used in our
study proved to be quite useful as a prognostic
determinant, in accordance with the findings of
others (Rosenfelt & Rosenberg, 1980; Hermann et
al., 1980; Weingrand et al., 1982).
Tumour size also proved to be of clinical
importance since among our patients those with
primary tumour > 10cm in diameter had a shorter
survival as a population compared with those
whose primary tumour was <10cm. This difference
proved to be statistically significant. Similar
conclusions have been reached by other
investigators previously (Shiu et al., 1982; Brooks
and Enterline, 1983).
Although we had the opportunity to study
accurately the depth of invasion of the gastric wall
in 20 patients, who underwent total or subtotal
gastrectomy, we were unable to demonstrate any
statistically significant correlation between depth of
invasion and survival. Our findings here are at
variance with those of other series (Lim et al., 1977;
Blackledge et al., 1979; Shiu et al., 1982; Brooks &
Enterline, 1983) demonstrating a negative
correlation between depth of invasion of the gastric
wall and survival. Possible explanations for this
discrepancy are the small numbers in each group of
patients and the administration of effective
"adjuvant" multichemotherapy in all our cases. A
third possibility may be related to the fact that no
cases with extension through the serosa into
adjacent organs, or complicating fistula or
performation, were included in the present series.
What constitutes the best treatment for primary
gastric lymphoma is presently a matter of active
debate. Most authors claim that surgery plus
postoperative irradiation is associated with the best
survival in limited disease (Joseph & Lates, 1966;
Shiu et al., 1982; Flemming et al., 1982; Shimm et
al., 1983). Nevertheless, since in most series,
irradiation is consistently given postoperatively it is
hardly possible to estimate its impact on survival.
On the other hand chemotherapy alone or in
combination with curative surgery and/or
irradiation has been has been used only rarely in
limited disease (Hande et al., 1978; Wiengrand et
al., 1982; Maor et al., 1984). This relucance
possibly stems from the knowledge that complete
response rate with chemotherapy is distinctly low in
cases of advanced gastrointestinal lymphomas
(Hande et al., 1978; Rosenfelt & Rosenberg, 1980)
while complications like perforation and gastro-
intestinal bleeding are not uncommon (Rosenfelt &
Rosenberg, 1980; Hermann et al., 1980; Weingrand
et al., 1982). Our results, in using chemotherapy
alone or combined with surgery where feasible, as
primary treatment of all stages of PGL, are
nevertheless encouraging; 18 out of 29 i.e. 62% of
patients so treated were found to be in complete
remission during extensive staging, after 6 courses
of chemotherapy. Only two of these patients have
relapsed so far with a median follow up of 31.5
months. Most important among the 20 patients
with curative surgery 15 (75%) were found to be in
complete remission after 6 courses of
chemotherapy. None of the patients treated with
chemotherapy after curative surgery developed
performation or gastrointestinal bleeding while one
of the nine with non resected tumour developed
massive gastrointestinal haemorrhage. The possible
beneficial effect of curative or debulking surgery,
before chemotherapy, in preventing bleeding and
performation has not been established although
there is suggestive evidence in the literature
(Weingrand et al., 1982).
Our experience of the use of multichemotherapy
as primary treatment in patients with unresected
tumours has been similar to that reported in the
literature (Hande et al., 1978; Rosenfelt &
Rosenberg, 1980). Only 3 out of 9 such patients i.e.
33% were found to have complete remission after 6
courses ofchemotherapy.
Finally no difference in survival has been
documented in relation to the chemotherapy
regimen. COP and CHOP proved to be equally
effective in the present study. This finding
nevertheless must be accepted with caution for two
reasons: (a) the numbers of patients in each
regimen are small and (b) since the assignment to
each treatment was not random we tended to treat
with CHOP the apparently ill patients.
In conclusion, on the basis of our present
findings we believe that: (a) curative surgery must
be always attempted in patients with primary
gastric lymphoma; (b) postoperative multi-
chemotherapy is essential in all patients found toPRIMARY GASTRIC LYMPHOMA 397
have more than stage I disease. The need for
postoperative chemotherapy in stage I patients has
to be investigated in a prospective randomized trial;
(c) the combination of curative surgery and
multichemotherapy in limited disease is an effective
therapeutic approach deserving further evaluation
in a prospective setting and (d) patients presenting
with unresectable tumour have a worse prognosis
despite multichemotherapy.
The authors thank Mr G. Pallikaris for his help in the
statistical analysis.
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